Flurbiprofen for the treatment of bone pain in patients with metastatic breast cancer

Two investigators enrolled 26 women with metastatic breast carcinoma in a six-week, double-blind, placebo-controlled, crossover study of flurbiprofen (Ansaid, Upjohn) and placebo. The study was designed to determine the efficacy of flurbiprofen in reducing bone pain due to metastatic breast cancer....

Full description

Saved in:
Bibliographic Details
Published inThe American journal of medicine Vol. 80; no. 3; pp. 83 - 87
Main Authors Lomen, Pavel L., Samal, Bohumil A., Lamborn, Kathleen R., Sattler, Linda P., Crampton, Sheri L.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 24.03.1986
Subjects
Adult
Aged
Bone and Bones
Breast Neoplasms - drug therapy
Carcinoma - drug therapy
Clinical Trials as Topic
Double-Blind Method
Female
Flurbiprofen - therapeutic use
Humans
Middle Aged
Pain - drug therapy
Placebos
Propionates - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Two investigators enrolled 26 women with metastatic breast carcinoma in a six-week, double-blind, placebo-controlled, crossover study of flurbiprofen (Ansaid, Upjohn) and placebo. The study was designed to determine the efficacy of flurbiprofen in reducing bone pain due to metastatic breast cancer. Pain score, overall performance, and concomitant use of narcotics were evaluated. The overall mean differences in pain scores between flurbiprofen and placebo showed better control of pain during treatment with flurbiprofen. None of these differences approached statistical significance. Evaluation of overall performance status reached statistical significance in one investigator's group. Three out of four patients reported decreased consumption of acetaminophen/aspirin plus codeine combinations while receiving flurbiprofen.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0002-9343
1555-7162
DOI:10.1016/0002-9343(86)90118-X